Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, TD Cowen Analyst Says

Key Points

• TD Cowen raised the price target for Gilead Sciences from $115.00 to $125.00 and maintains a "buy" rating, suggesting a potential upside of 3.05% from the previous close.
• Insiders, including CFO Andrew D. Dickinson, have recently sold shares of Gilead, totaling $8.28 million in stock sales during the last quarter.
• Gilead reported $2.01 earnings per share, exceeding estimates by $0.05, and had revenue of $7.08 billion for the last quarter.

Gilead Sciences (NASDAQ:GILD - Get Free Report) had its price target boosted by stock analysts at TD Cowen from $115.00 to $125.00 in a research report issued on Thursday,MarketScreener reports. The firm currently has a "buy" rating on the biopharmaceutical company's stock. TD Cowen's target price would suggest a potential upside of 3.05% from the company's previous close.

Other equities research analysts have also issued research reports about the company. The Goldman Sachs Group upped their price target on Gilead Sciences from $105.00 to $108.00 and gave the company a "neutral" rating in a research report on Friday, October 17th. UBS Group upped their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Wolfe Research increased their target price on shares of Gilead Sciences from $135.00 to $140.00 and gave the company an "outperform" rating in a research report on Thursday. Royal Bank Of Canada upped their price objective on shares of Gilead Sciences from $98.00 to $100.00 and gave the company a "sector perform" rating in a research note on Wednesday, October 8th. Finally, Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price on the stock in a report on Friday, July 25th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $122.61.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $121.30 on Thursday. The business has a 50 day moving average of $115.38 and a 200-day moving average of $110.78. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences has a 1 year low of $86.08 and a 1 year high of $124.61. The company has a market capitalization of $150.51 billion, a P/E ratio of 24.19, a P/E/G ratio of 0.85 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company's revenue was up 1.4% on a year-over-year basis. During the same period in the prior year, the company posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities research analysts predict that Gilead Sciences will post 7.95 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $354,240.00. Following the transaction, the insider owned 110,193 shares of the company's stock, valued at approximately $13,011,589.44. This trade represents a 2.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the transaction, the chief financial officer owned 157,055 shares in the company, valued at $18,545,054.40. This represents a 1.57% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 71,500 shares of company stock worth $8,281,540 in the last quarter. Insiders own 0.27% of the company's stock.

Institutional Trading of Gilead Sciences

A number of institutional investors have recently modified their holdings of GILD. Vanguard Group Inc. raised its holdings in Gilead Sciences by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company's stock valued at $13,233,912,000 after acquiring an additional 1,893,401 shares during the period. Geode Capital Management LLC boosted its stake in Gilead Sciences by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company's stock worth $3,231,548,000 after purchasing an additional 727,515 shares during the period. Norges Bank purchased a new position in Gilead Sciences during the 2nd quarter valued at about $2,150,268,000. Price T Rowe Associates Inc. MD increased its position in shares of Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock valued at $1,647,484,000 after buying an additional 11,156,382 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Gilead Sciences by 12.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company's stock worth $1,541,302,000 after buying an additional 1,520,809 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.